Dereiah Saedah, Ghori Muhammad Usman, Conway Barbara R
Department of Pharmacy, University of Huddersfield, Huddersfield HD1 3DH, UK.
Institute of Skin Integrity and Infection Prevention, University of Huddersfield, Huddersfield HD1 3DH, UK.
Pharmaceutics. 2024 Dec 27;17(1):27. doi: 10.3390/pharmaceutics17010027.
Spironolactone (SP), an aldosterone inhibitor widely used to treat androgen-dependent disorders such as acne, hirsutism, and alopecia, has demonstrated therapeutic potential in both oral and topical formulations. However, SP's low solubility and poor bioavailability in conventional formulations have driven the development of novel nanocarriers to enhance its efficacy. This review systematically examines recent advancements in SP-loaded nanocarriers, including lipid nanoparticles (LNPs), vesicular nanoparticles (VNPs), polymeric nanoparticles (PNPs), and nanofibers (NFs). A search strategy was developed, and the relevant literature was systematically searched using databases such as Scopus, PubMed, and Google Scholar. The review process, including screening, inclusion, and exclusion criteria, adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A comprehensive analysis of 13 eligible research articles, corresponding to 15 studies, highlights key aspects such as encapsulation efficiency, stability, particle size, and in vitro and in vivo efficacy. Six studies focused on lipid nanoparticles (LNPs), including solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), which were found to improve SP's bioavailability and skin permeation. Another six studies investigated vesicular nanoparticles (VNPs), such as ethosomes and niosomes, demonstrating superior skin targeting and penetration capabilities. Two studies on polymeric nanoparticles (PNPs) showed effectiveness in delivering SP to hair follicles for the treatment of alopecia and acne. Additionally, one study on SP-loaded nanofibers indicated significant potential for topical rosacea therapy. SP-loaded nanocarrier systems represent promising advancements in targeted topical therapy. However, further clinical studies are required to optimize their safety, efficacy, and delivery mechanisms.
螺内酯(SP)是一种广泛用于治疗痤疮、多毛症和脱发等雄激素依赖性疾病的醛固酮抑制剂,已在口服和外用制剂中显示出治疗潜力。然而,SP在传统制剂中的低溶解度和差的生物利用度推动了新型纳米载体的开发,以提高其疗效。本综述系统地研究了载SP纳米载体的最新进展,包括脂质纳米颗粒(LNPs)、囊泡纳米颗粒(VNPs)、聚合物纳米颗粒(PNPs)和纳米纤维(NFs)。制定了搜索策略,并使用Scopus、PubMed和谷歌学术等数据库系统地搜索了相关文献。综述过程,包括筛选、纳入和排除标准,遵循系统评价和Meta分析的首选报告项目(PRISMA)指南。对13篇符合条件的研究文章(对应15项研究)的综合分析突出了包封效率、稳定性、粒径以及体外和体内疗效等关键方面。六项研究聚焦于脂质纳米颗粒(LNPs),包括固体脂质纳米颗粒(SLNs)和纳米结构脂质载体(NLCs),发现它们可提高SP的生物利用度和皮肤渗透性。另外六项研究调查了囊泡纳米颗粒(VNPs),如醇质体和非离子表面活性剂囊泡,显示出卓越的皮肤靶向和渗透能力。两项关于聚合物纳米颗粒(PNPs)的研究表明,将SP递送至毛囊用于治疗脱发和痤疮具有有效性。此外,一项关于载SP纳米纤维的研究表明其在局部治疗酒渣鼻方面具有巨大潜力。载SP纳米载体系统代表了靶向局部治疗中很有前景的进展。然而,需要进一步的临床研究来优化其安全性、疗效和递送机制。